Study of Tofacitinib in Refractory Dermatomyositis: An Open‐Label Pilot Study of Ten Patients

This is the first prospective, open-label clinical trial of tofacitinib in DM that demonstrates strong clinical efficacy of a pan-JAK inhibitor, as measured by validated myositis response criteria. Future randomized controlled trials using JAK inhibitors should be considered for treating DM.